文献速递免疫规划

两种新型丙型肝炎病毒多表位疫苗的免疫原性研究

Immunity of two novel hepatitis C virus polyepitope vaccines.
PubMed 文献 · Vaccine · 2022-09-20

研究构建了表达HCV E1/E2多表位(R9-Bp)及LTB佐剂融合蛋白(LTB-R9-Bp)的重组载体,在BALB/c小鼠中比较腹腔、肌内和口服免疫的体液免疫应答。腹腔免疫LTB-R9-Bp峰值抗体滴度1:341000,高于R9-Bp的1:85000(P=0.0036或0.0002);两种蛋白诱导的IFN-γ和IL-4水平相似,抗血清可识别天然E1/E2并显著抑制HCV进入(P<0.0001)。

要点

  • R9-Bp和LTB-R9-Bp腹腔或肌内免疫均诱导强烈体液免疫,口服免疫未诱导。
  • 腹腔免疫LTB-R9-Bp峰值滴度1:341000,高于R9-Bp的1:85000(P=0.0036或0.0002)。
  • 两种蛋白诱导的抗血清识别天然HCV E1/E2并显著抑制病毒进入(P<0.0001)。

核心结论

  • 基于大肠杆菌表达的R9-Bp和LTB-R9-Bp有望成为丙型肝炎病毒疫苗候选。

研究设计与样本

  • 构建pET-R9-Bp和pET-LTB-R9-Bp重组载体,在大肠杆菌中表达并纯化蛋白。
  • 在BALB/c小鼠中经腹腔、肌内或口服途径免疫,评估体液免疫应答。

主要发现

  • 腹腔免疫LTB-R9-Bp峰值抗体滴度1:341000,高于R9-Bp的1:85000(P=0.0036或0.0002)。
  • 肌内免疫两种蛋白峰值滴度相当,但第二次加强后一周差异有统计学意义(P=0.0032)。
  • 两种蛋白诱导IFN-γ和IL-4分泌水平相似。
  • 两种蛋白诱导的抗血清识别天然HCV E1和E2蛋白。
  • HCV特异性抗血清显著抑制HCV进入(P<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatitis C virus (HCV) infection remains a serious public health burden around the world. So far there is no effective vaccine against this virus. Neutralizing antibody (NAb) responses to the epitopes within HCV E1 and E2 proteins are related to the resolution of hepatitis C infection. E. coli heat-labile enterotoxin B subunit (LTB) has been described as potent immunity adjuvants. In this study, we constructed recombinant pET vectors: pET-R9-Bp (B cell polyepitopes) expressing 7 epitopes from HCV E1 and E2 proteins including R9 (E2384-411aa)-Bp (E1313-327aa-E2396-424aa-E2436-447aa-E2523-540aa-E2610-627aa-E2631-648aa) and pET-LTB-R9-Bp expressing LTB adjuvant in combination with R9-Bp. Recombinant proteins R9-Bp and LTB-R9-Bp were expressed successfully in E. coli and purified by the Ni-NTA column. Both R9-Bp and LTB-R9-Bp in BALB/c mice induced robust humoral immune response in the context of intraperitoneal or intramuscular immunization but not oral immunization. Intraperitoneal administration of LTB-R9-Bp induced a higher antibody titer (peak titer: 1:341000) than that of R9-Bp (peak titer: 1:85000) after the second boost (P = 0.0036 or 0.0002). However, comparable antibody peak titers were elicited for both R9-Bp and LTB-R9-Bp in intramuscular immunization albeit with significant difference (P = 0.0032) a week after the second boost. In addition, both R9-Bp and LTB-R9-Bp induced the secretion of cytokines including IFN-γ and IL-4 at similar levels. anti-sera induced by both R9-Bp and LTB-R9-Bp recognized native HCV E1 and E2 proteins. Moreover, these HCV-specific antisera inhibited significantly the entry of HCV (P < 0.0001). Taken together, these findings showed that E. coli-based both R9-Bp and LTB-R9-Bp could become promising HCV vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Feng T, Li M, Zhang L, et al. Immunity of two novel hepatitis C virus polyepitope vaccines. Vaccine. 2022. PMID: 36150975. doi:10.1016/j.vaccine.2022.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。